Douglas D L, Duckworth T, Russell R G, Kanis J A, Preston C J, Preston F E, Prenton M A, Woodhead J S
Lancet. 1980 May 17;1(8177):1043-7. doi: 10.1016/s0140-6736(80)91496-8.
30 patients with disorders of calcium metabolism were treated with dichloromethylene diphosphonate (C1(2)MDP, or clodronate disodium), an inhibitor of bone resorption. 13 patients with Paget's disease of bone were given C1(2)MDP by mouth (1.6 g/day). Serum-alkaline-phosphatase and urinary hydroxyproline fell to normal or near-normal within 3-7 months, and there was a clinical improvement in all but 1 patient. C1(2)MDP (0.8-3.2 g/day) also reduced plasma-calcium and urinary calcium in 17 patients with hypercalcaemia due to primary hyperparathyroidism or secondary to malignant disease. C1(2)MDP seems to be an effective oral drug for inhibiting excessive bone resorption in man.
30例钙代谢紊乱患者接受了骨吸收抑制剂二氯亚甲基二膦酸盐（C1(2)MDP，即氯屈膦酸二钠）治疗。13例骨Paget病患者口服C1(2)MDP（1.6克/天）。血清碱性磷酸酶和尿羟脯氨酸在3至7个月内降至正常或接近正常，除1例患者外所有患者临床症状均有改善。C1(2)MDP（0.8 - 3.2克/天）还使17例因原发性甲状旁腺功能亢进或继发于恶性疾病导致高钙血症的患者血浆钙和尿钙降低。C1(2)MDP似乎是一种抑制人体过度骨吸收的有效口服药物。
